Moderna Stock News

BTCS (BTCS) -10%.Novavax (NVAX) -10%.Standard Lithium (SLI) -7%.Singularity Future Technology (SGLY) -6%.Orchid Island Capital ORC -6% after dividend cut due to margin

If the data are supportive and, subject to regulatory consultation, Moderna may proceed with regulatory filings

These are the stocks posting the largest moves before the bell.

Moderna said that it plans to report data on its COVID-19 vaccine in children between the ages of 2 and 5 years old in March, Bloomberg reports.

Someone with a lot of money to spend has taken a bullish stance on Moderna (NASDAQ: MRNA ). And retail traders should know. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga. Whether this is an institution or just a wealthy individual, we don''t know. But when something this big happens with MRNA, it often means somebody knows something is about to happen. So how do we know what this whale just did? Today, Benzinga ''s options scanner spotted 12 uncommon options trades for Moderna. This isn''t normal. The overall sentiment of these big-money traders is split between 66% bullish and 33%, bearish. Out of all of the special options we uncovered, 5 are Full story available on Benzinga.com

Moderna (MRNA) shares failed to rally on Tuesday despite Fed Chair Powell talking calmly to Capitol Hill and soothing most equities in the process. Ri

Bill Gates Flip Flops After Turning Omicron ''FUD'' Up To ''11'' After initially turning the "FUD" dial up to ''11'' in response to the initial reports and data about the omicron variant, Microsoft founder and billionaire wannabe global vaccine czar Bill Gates has apparently had a change of heart. Gates on Tuesday joined Professor Devi Sridhar, a professor and chair of global health policy at the University of Edinburgh, for a Twitter discussion about the COVID pandemic. Following a few questions about vaccines where Gates seems to actually acknowledge their shortcomings for once, Gates tells Dr. Sridhar that after an omicron wave has subsided, the rest of the year should see far fewer cases and deaths, leaving COVID to retreat to the intensity of a bad flu. "Once Omicron goes through a country then the rest of the year should see far fewer cases so Covid can be treated more like seasonal flu." A more infectious variant is "not likely," according to Gates, although he acknowledges that the world has been "surprised a lot" before, and that the WHO is already hard at work trying to prepare for the "next" pandemic.

A new real-world study funded by the Department of Veterans Affairs (VA) showed that compared to those who received Pfizer Inc''s (NYSE: PFE ) COVID-19 vaccine, Moderna Inc (NASDAQ: MRNA ) vaccine recipients had a significantly lower risk of SARS-CoV-2 infection and related hospitalizations . Lower risk was observed across all age groups, comorbidity-burden categories, and Full story available on Benzinga.com

This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice. (Tuesday Market Open) Equity index futures are pointing higher as investors hope to build on Mondays rebound. Monday was a wild day with the stock market living up to its roller coaster reputation. However, with Federal Reserve Chairman Jerome Powell meeting with the Senate today, investors could still be a bit skittish. Stocks sold off on the open, with the S&P 500 (SPX) dropping 1.85% in the first hour but rallied off intraday lows to trim much of its losses. The S&P 500 closed down just 0.14%. The Nasdaq Composite ((COMP:GIDS)) led the selloff, falling 2.5% in the first hour of trading and easily broke the 14,900 support level. The next level of support would be around October 2021 lows near 14,200. However, the bulls refused to concede the line and pushed back to allow the Nasdaq to close 0.05% higher on a crazy day of trading. After spiking up over 23, the VIX ( Cboe Market Volatility Index ) subsided back below 21 as stocks rallied off their mid-day lows and closed at 19.33.

Futures Rebound As Fed-Induced Rout Finally Eases After yesterday''s miraculous tech recovery which saw gigacaps drop as much as 4% before recovering all losses and closing green, Nasdaq futures led gains among U.S. stock-index futures, hinting at further relief for technology stocks as Treasury yields retreated in early trading but have since steadied around 1.75%, unchanged from Monday. Nasdaq futures rose as much as 0.7%, while S&P 500 and Dow Jones contracts were also higher by about 0.4% ahead of Powells Senate confirmation hearing for second term as Fed chair which begins at 10am and where the Fed chair is expected to put on a dovish mask and walk back some of the recent hawkish commentary. Dip-buyers rescued the Nasdaq from a fifth session of declines on Monday after Marko Kolanovic urged JPM clients to buy the dip, writing that yields aren''t too high and the Fed''s won''t derail the economys rebound. We view the recent equity volatility as an adjustment to the Feds incrementally more hawkish stance, rather than a sign that the Fed is about to bring the recovery and the equity rally abruptly to an end, Mark Haefele, chief investment officer at UBS Global Wealth Management, said in a note. We now expect three Fed rate hikes this year, starting as soon as March. We are looking for opportunities to raise our weighting in stocks in 2022, according to Luca Paolini, chief strategist at Pictet Asset Management, whose firm has a neutral stance on equities. The global recovery remains resilient, thanks to a strong labor market, pent-up demand for services and healthy corporate balance sheets. In his second term confirmation hearing before the Senate Banking Committee at 10am ET today, Fed Chair Jerome Powell will say the central bank will keep inflation from becoming entrenched, but the post-pandemic economy may look different from previous expansions.

The study found Moderna''s COVID-19 to be the most effective in preventing severe illness and deaths.

Moderna (MRNA) closed as the best performer in the S&P 500 as investors propelled the beaten-down biotech after the company painted an upbeat outlook for its blockbuster COVID-19

Fourth Turning 2022: Bad-Moon Rising Authored by Jim Quinn via The Burning Platform blog, Try to unlearn the obsessive fear of death (and the anxious quest for death avoidance) that pervades linear thinking in nearly every modern society. The ancients knew that, without periodic decay and death, nature cannot complete its full round of biological and social change. Without plant death, weeds would strangle the forest. Without human death, memories would never die, and unbroken habits and customs would strangle civilization. Social institutions require no less. Just as floods replenish soil and fires rejuvenate forests, a Fourth Turning clears out societys exhausted elements and creates an opportunity. Strauss & Howe The Fourth Turning Institutions will be increasingly bossy, limiting personal freedoms, chastising bad manners, and cleansing the culture. Powerful new civic organizations will make judgments about which individual rights deserve respect and which do not. Criminal justice will become swift and rough, trampling on some innocents to protect an endangered and desperate society from those feared to be guilty.

100 "Fringe" Predictions For 2022 Submitted by QTR''s Fringe Finance Having already provided my semi-lengthy look at 22 stocks that I am watching heading into 2022 (you can view that far more serious post here ), I wanted to do something more fun, and less serious to open the new year. Heading into each new year, contained herein are 80 predictions of mine - void of all analysis and disclaiming any and all guarantees that I have any idea what I’m talking about . Absolutely none of these are to be considered life advice, investment advice or solicitations to buy or sell securities, sectors or industries mentioned. Please note that I have personal financial exposure to some elements in this list and that these are nothing more than wild-ass guesses, for fun, of what I think the coming year could bring. This list is for fun only - and is all opinion only. Photo: Diginomica It’ll be fun to look back at these predictions next year, when I make a similar list for 2023. And hey, at the very least, this list will serve as a handy reference guide as to how not worth it a paid subscription to my blog can be!

Moderna <> has staged a sharp rally to lead the components of S&P 500 after the Cambridge, Massachusetts-based biotech raised its guidance for 2022 COVID-19 vaccine sales.Speaking